Morgan Stanley lowered the firm’s price target on BridgeBio Oncology (BBOT) to $18 from $20 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
- BridgeBio Oncology reports promising RAS and PI3Kα data
- BridgeBio Oncology announces new clinical data across 3 pipeline programs
- BridgeBio Oncology initiated with an Overweight at Morgan Stanley
- BridgeBio Oncology: Positioned for Growth with Innovative RAS-Targeted Therapies